US pharmaceutical major Eli Lilly & Co. (NYSE: LLY) has announced the official market launch of its drug Mounjaro (tirzepatide) in China, expanding access to this treatment for patients in the region.
Coverage of Two Indications
The launch of Mounjaro in China covers two specific indications. The first is for the treatment of type 2 diabetes mellitus (T2DM) in patients who have not achieved adequate blood glucose control with metformin or sulfonylurea drugs. The second indication is for long-term weight management in adults with a body mass index (BMI) of 28 kg/m2 or higher (obesity) or 24 kg/m2 or higher (overweight) and at least one weight-related complication. Such complications include hypertension, dyslipidemia, hyperglycemia, obstructive sleep apnea, and cardiovascular disease, among others. These indications were approved by the Chinese regulatory authorities in May and July of the previous year, respectively.
Enhancing Treatment Options
The introduction of Mounjaro in China not only provides an additional option for the management of type 2 diabetes but also addresses the significant need for effective weight management solutions in the country. By offering this dual therapy, Eli Lilly & Co. is poised to make a significant impact on public health in China, particularly for those struggling with diabetes and obesity.-Fineline Info & Tech
